EUVIMEDEUVIMED entdecken
Kohortenstudie

Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study

L Hulst, S Cappuyns, F Peeters, F Vulsteke, F Van Herpe, E Van Cutsem, J Dekervel

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.06.004 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von L Hulst und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastro-enterology and Hepatology, Digestive Oncology, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Disease Progression, Microsatellite Instability. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: About one third of patients with deficient mismatch repair/microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC) experience primary resistance or early progression on immune checkpoint inhibitors (ICI), while others benefit from exceptionally long-lasting responses. In this single-centre retrospective study, we aimed to identify variables associated with improved overall survival (OS) as well as early disease progression. METHODS: All dMMR/MSI-H mCRC patients treated with ICI between 2014 and 2022 were included. Baseline patient demographics, tumour characteristics as well response and outcome data were recorded. OS was estimated using the Kaplan-Meier method. Uni- and multivariate cox regression analysis was used to identify parameters associated with improved OS. Clinicopathological factors associated with early progression (≤ 12 months after treatment initiation) were assessed using uni- and multivariate logistic regression analysis. RESULTS: About 84 ICI-treated dMMR/MSI-H mCRC patients were included. Progressive disease occurred in 37 (44%) patients, but only in 11 (19%) patients with disease control at 12 months. Median OS was 80 months and improved outcome was associated with a lower neutrophile-to-lymphocyte ratio (NLR) (P = .004) and the presence of immune-related adverse events (irAEs) (P = .015). Early progression was associated with poor performance status (P = .036), a higher blood CRP level (P = .033) and absence of irAEs (P = .002). CONCLUSION: Disease progression in ICI-treated dMMR/MSI-H mCRC rarely occurs in patients experiencing disease control for at least 12 months. Performance status, presence of immune-related adverse events, CRP levels, CEA levels and NLR can be helpful to identify those patients that may benefit from ICI treatment, guiding clinicians in therapeutic decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsDisease ProgressionMicrosatellite InstabilityHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAdultDNA Mismatch RepairAged, 80 and over

Stichwörter der Autor:innen

BiomarkersDurable disease controlGI oncologyImmunotherapyMicrosatellite-instability-high

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gastro-enterology and Hepatology, Digestive Oncology, University Hospitals Leuven (UZ Leuven), Leuven, Belgium.
  • Department of Gastro-enterology and Hepatology, Digestive Oncology, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. Electronic address: jeroen.dekervel@uzleuven.be.

Zitieren

APA

Hulst, L., Cappuyns, S., Peeters, F., Vulsteke, F., Van Herpe, F., Van Cutsem, E., & Dekervel, J. (2024). Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.06.004

Vancouver

Hulst L, Cappuyns S, Peeters F, Vulsteke F, Van Herpe F, Van Cutsem E, et al. Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.06.004

BibTeX
@article{Hulst2024,
  author = {Hulst, L and Cappuyns, S and Peeters, F and Vulsteke, F and Van Herpe, F and Van Cutsem, E and Dekervel, J},
  title = {Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.06.004}
}
Kostenlos starten →